Poly(ADP-ribose) Polymerase Inhibitors
"Poly(ADP-ribose) Polymerase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.
| Descriptor ID |
D000067856
|
| MeSH Number(s) |
D27.505.519.389.739 D27.505.954.248.692
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerase Inhibitors".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in this website by year, and whether "Poly(ADP-ribose) Polymerase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 3 | 2 | 5 |
| 2010 | 4 | 0 | 4 |
| 2011 | 7 | 1 | 8 |
| 2012 | 3 | 6 | 9 |
| 2013 | 2 | 1 | 3 |
| 2014 | 7 | 5 | 12 |
| 2015 | 6 | 2 | 8 |
| 2016 | 5 | 7 | 12 |
| 2017 | 13 | 12 | 25 |
| 2018 | 12 | 2 | 14 |
| 2019 | 20 | 5 | 25 |
| 2020 | 17 | 7 | 24 |
| 2021 | 18 | 5 | 23 |
| 2022 | 1 | 17 | 18 |
| 2023 | 5 | 16 | 21 |
| 2024 | 11 | 9 | 20 |
To return to the timeline,
click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.
-
Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare. Int J Gynecol Cancer. 2024 Nov 04; 34(11):1661-1670.
-
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024 Nov; 19(6):879-892.
-
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol. 2024 Nov; 190:255-261.
-
Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy. Mol Cancer Res. 2024 09 04; 22(9):840-851.
-
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer. 2024 Nov; 131(9):1400-1414.
-
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int J Mol Sci. 2024 Aug 26; 25(17).
-
Strategies for the prevention or reversal of PARP inhibitor resistance. Expert Rev Anticancer Ther. 2024 Oct; 24(10):959-975.
-
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers. Cancer Discov. 2024 Aug 02; 14(8):1476-1495.
-
Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib. JCO Precis Oncol. 2024 Aug; 8:e2400303.
-
Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med. 2024 Aug; 13(15):e70031.